Opinion|Videos|March 13, 2026
Sequencing Considerations in Advanced EGFR-Mutated NSCLC
Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss sequencing strategies in advanced EGFR-mutated NSCLC.
Advertisement
Episodes in this series
Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, explore optimal sequencing strategies following frontline EGFR-directed therapy in EGFR-mutated non–small cell lung cancer. Vokes reviews mechanisms of acquired resistance and the role of repeat molecular testing at progression. Devarakonda highlights how emerging targeted therapies and combination regimens may influence second- and later-line treatment planning.
Advertisement
Related to this article
Long-term follow-up showed pTVG-HP nearly doubled median OS compared with placebo in biochemically recurrent prostate cancer.
The FDA has granted fast track designation for safusidenib in IDH1-mutant glioma, with a phase 3 trial on the way.
Dana-Farber research aided in the FDA approval of iberdomide-based therapy in relapsed/refractory multiple myeloma.
Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.
The FDA has granted 68Ga-NYM096 breakthrough therapy and fast track designations for imaging ccRCC.
The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.
Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, which is being evaluated for pancreatic ductal adenocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
2
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
3
Dr Skoulidis on First-Line Divarasib Plus Pembrolizumab in KRAS G12C+ NSCLC
4
Dr Cortés on Developing CD47 as a Biomarker in Pretreated HER2+ Breast Cancer
5